Bill
H 1347
Massachusetts bill strengthens sickle cell disease care through healthcare system improvements, likely addressing insurance coverage, treatment access, and specialized care protocols.
H 1347 aims to enhance sickle cell disease care and treatment in Massachusetts through legislative improvements to the state's healthcare system. The bill's specific provisions are not detailed in the available legislative history, though its evolution (being accompanied by a new draft as H 4555) suggests substantive revisions during the legislative process. The measure received a committee hearing in June 2025 and was referred to the Financial Services Committee, indicating potential insurance, coverage, or funding mechanisms are involved.
Sickle cell disease disproportionately affects Black Americans and causes significant morbidity and mortality, making targeted policy improvements a public health priority. Enhanced state-level care protocols, coverage requirements, or funding mechanisms could improve access to specialized treatment, pain management, and preventive services for Massachusetts residents with this genetic blood disorder. Legislative action on rare diseases often requires dedicated attention since market incentives alone may not drive adequate medical infrastructure or pharmaceutical development.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
